RETA/CAG

RETA/CAG is a formulated blend of retatrutide and cagrilintide, not a single compound and not a two-strength GLP-3 RT pack. The components are presented together for laboratories studying multi-component documentation and handling workflows.

A blend has no single CAS number and no single purity figure that meaningfully describes both components. Certificate review should address identity and ratio questions.

Never share COAs with GLP-3 RT 10mg or 20mg — those are single-sequence retatrutide SKUs with separate lots.

Cagrilintide has been studied as a long-acting amylin analogue in weight-management research, including combination protocols with semaglutide in clinical literature describing pharmaceutical products.

Retatrutide literature is summarised on the Retatrutide encyclopedia page. Combining those literatures does not create a clinical claim for this research blend.

Blend COAs should let you connect each named component to analytical evidence where testing was performed. A single main-peak figure is not sufficient characterisation of a two-component mixture.

Store sealed at 2–8 °C. RETA/CAG is not an approved medicine and is not for human use.

Supplied strictly for in vitro laboratory research against a research-use declaration. The catalog presentation is a 15 mg lyophilised blend vial.

Blend procurement simplifies inventory for laboratories that deliberately study multi-component materials, but it complicates certificate reading. Ask whether both named components are identified and whether the reported ratio matches the label before releasing the vial into experimental use.

Cagrilintide-class material brings amylin-pathway literature into the same vial as retatrutide-class material. That combination is a documentation choice by the catalog, not a claim that the published single-agent literatures apply unchanged to the mixture.

If a study later needs unambiguous single-substance evidence, order GLP-3 RT 10mg or 20mg separately rather than attempting to reinterpret a blend certificate as a single-component release.

This monograph is a reference article for laboratory purchasers and documentation staff. It summarises chemical identity, literature context and handling constraints that affect analytical work. It is not a protocol, not a dosing guide and not a substitute for institutional SOP review.

Where pharmaceutical or clinical papers are cited, they are included only to anchor compound identity and regulatory status. They do not authorise human use of VaultLabs research material, and they do not convert a lyophilised reference vial into a finished medicine.

If a certificate, label and monograph appear to disagree, stop and query support with the lot number before the material enters an experiment. Lot-linked certificates override general catalog copy for the specific unit in hand.

VaultLabs updates monographs when catalog strengths or documentation practice change. The updatedAt field marks the editorial revision date for this article, not the manufacture date of any particular lot.

All VaultLabs materials named here remain research-use-only: not for human consumption, not for medical use, and not for personal application under any reading of the surrounding literature.

Multi-component incretin / amylin-pathway documentation

Blend identity and ratio analytics

Comparative single-vs-blend handling workflows

2–8 °C (lyophilized, sealed)

2–8 °C sealed; follow product page and batch COA notes.

Blend materials inherit the strictest handling constraints of either component — gentle reconstitution and sealed cold storage.